US11612566 — Lamotrigine oral liquid suspension and use thereof
Method of Use · Assigned to OWP Pharmaceuticals Inc · Expires 2040-05-29 · 14y remaining
What this patent protects
This patent protects an oral liquid suspension of lamotrigine and methods of medical treatment using the suspension.
USPTO Abstract
The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.
Drugs covered by this patent
- Lamictal (lamotrigine) · GSK
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4271 |
— | Lamictal |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.